2013
Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States.
Walensky RP, Sax PE, Nakamura YM, Weinstein MC, Pei PP, Freedberg KA, Paltiel AD, Schackman BR. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Annals Of Internal Medicine 2013, 158: 84-92. PMID: 23318310, PMCID: PMC3664029, DOI: 10.7326/0003-4819-158-2-201301150-00002.Peer-Reviewed Original Research
2012
The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women
Walensky RP, Park JE, Wood R, Freedberg KA, Scott CA, Bekker LG, Losina E, Mayer KH, Seage GR, Paltiel AD. The Cost-effectiveness of Pre-Exposure Prophylaxis for HIV Infection in South African Women. Clinical Infectious Diseases 2012, 54: 1504-1513. PMID: 22474224, PMCID: PMC3334365, DOI: 10.1093/cid/cis225.Peer-Reviewed Original ResearchConceptsPre-exposure prophylaxisSouth African womenHIV infectionRecent trialsHIV riskLife expectancyHuman immunodeficiency virus (HIV) infectionAfrican womenIncremental cost-effectiveness ratioImmunodeficiency virus infectionAge-adjusted incidenceShort-term efficacyHIV infection incidenceHIV natural historyCost-effectiveness ratioPopulation-level transmissionPrEP efficacyHIV acquisitionLong-term impactPatient outcomesPopulation demographic characteristicsVirus infectionClinical cohortInfection incidenceCost savings
2009
HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness
Paltiel AD, Freedberg KA, Scott CA, Schackman BR, Losina E, Wang B, Seage GR, Sloan CE, Sax PE, Walensky RP. HIV Preexposure Prophylaxis in the United States: Impact on Lifetime Infection Risk, Clinical Outcomes, and Cost-Effectiveness. Clinical Infectious Diseases 2009, 48: 806-815. PMID: 19193111, PMCID: PMC2876329, DOI: 10.1086/597095.Peer-Reviewed Original Research